抗Pgp抗体PHMA02在肿瘤临床中的应用研究及预后分析

Clinical Application of Anti-Pgp Monoclonal Antibody PHMA02 and It′s Prognostic Significance in Malignant Tumors

目的：应用单抗ＰＨＭＡ０２ 对１４８ 例肿瘤患者Ｐ－ 糖蛋白（Ｐｇｐ）的表达进行检测，并对该单抗的特异性、检测结果与临床符合率以及预后的准确性进行评估。方法：应用免疫组化法检测了４７ 例实体瘤标本，应用药敏实验检测１５ 例儿童恶性肿瘤；应用间接免疫荧光法、ＲＴ－ ＰＣＲ 法和药敏实验检测了１０１ 例急性白血病（ＡＬ） 患者；用医学统计软件分析数据。结果：１） 在４７ 例实体瘤标本中，儿童恶性肿瘤中多药耐药阳性（ ＭＤＲ＋） 表达率较高（８６７ ％） ，乳腺癌淋巴结转移灶中ＭＤＲ＋ 表达率为６６７％ ，显著高于乳腺癌原发灶的３００ ％ （ Ｐ＜ ００１） 。２） 在１０１ 例急性白血病（ＡＬ） 患者中，难治和复发组的ＭＤＲ＋ 表达率（５２９ ％ ）显著高于初诊组（１９２ ％ ）（ Ｐ＜ ００１）。３） 单抗ＰＨＭＡ０２ 的检测结果与国外同型单抗ＪＳＢ－ １ 的平行检测结果呈正的直线相关（ Ｐ＜００５） ，与ＲＴ－ ＰＣＲ 的检测结果具有相关性（Ｐ＜ ００１） ；部分标本的药敏实验结果与单抗ＰＨＭＡ０２ 的检测结果基本一致。结论：１） 单抗ＰＨＭＡ０２ 的检测结果与临床有较好的符合率，可在临床上应用。２）Ｐｇｐ 在成人肺癌和乳腺癌中均有一?

Objective: Using monoclonal antibody PHMA02, we determined the expression of Pgp in 148 patients with cancers The specificity of PHMA02 concordance rate between delectability and clinical outcome and accuracy of prognosis were evaluated Methods: Indirect immunofluorescence, immunochemistry assay, RT-PCR and chemosensitivity test were used to analyse the expression of mdr1 gene in 47 solid tumor specimens and 101 acute leukemia patients respectively The data were analysed statistically Results: 1) In 47 solid tumor specimens, the expression rate of MDR +was relatively higher in children with malignant tumor(86 7%) In breast cancer, the expression rate of MDR +in metastatic focus (66 7%) was significantly higher than that in primary ones (30 0%)( P<0 01 ) 2) In 101 Al patients, the expression rate of MDR +in refractory-relapsed group (52 9%) was significantly higher than that in untreated group (19 2%) ( P<0 01 ) 3) The results of detection with PHMA02 antibody parallelled to that of JSB-land RT-PCR ( P<0 05 ) The results of anticancer drugs sensitivity corresponded with those of PHMA02 Conclusion: 1) The results of detection with PHMA02 antibody concorded well with drug resistance in AL clinically and showed that the antibody can be used in clinic 2) The Pgp expression can be detected in lung cancer, breast cancer, and it was higher in children with malignant tumor and the expression of MDR +correlates well with the recurrence and metastasis of tumor 3) The MDR -patients in untreated group had a good prognosis and the CR rate was higher On the contrary, the MDR +patients in refractory-relapsed group had a poor prognosis Therefore, expression of Pgp in these two groups is a valuable factor for predicting chemotherapy response and prognosis